Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use

Kenneth H. Eckels, Yu Yong-Xin, Doria R. Dubois, Nyven J. Marchette, Dennis W. Trent, Anthony J. Johnson

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The Japanese encephalitis (JE) live-attenuated vaccine virus clone SA14-14-2 was adapted to grow in primary canine kidney (PCK) cell culture, and vaccine seeds and a first lot of vaccine were prepared in these cells. Characterization of the PCK-grown virus by various laboratory and animal tests indicated that passage in PCK did not result in detectable phenotypic or genome changes for this virus clone. Markers of attenuation included small plaque size, lack of intracerebral virulence for weanling mice, minimal neurovirulence for rhesus monkeys and a distinct nucleotide pattern compared to the parent SA14 non-attenuated virus. In addition, the seeds and vaccine were free of any detectable adventitious microbial agents that would render these materials unsafe for human immunization. Small-scale clinical trials of the JE SA14-14-2 PCK vaccine can now proceed to test the human safety of this product.

Original languageEnglish (US)
Pages (from-to)513-518
Number of pages6
JournalVaccine
Volume6
Issue number6
DOIs
StatePublished - 1988

Fingerprint

Japanese Encephalitis Virus
Japanese encephalitis virus
Attenuated Vaccines
live vaccines
kidney cells
Canidae
cell culture
Vaccines
Cell Culture Techniques
Japanese Encephalitis
vaccines
Viruses
Kidney
viruses
dogs
kidneys
encephalitis
Seeds
Clone Cells
clones

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. / Eckels, Kenneth H.; Yong-Xin, Yu; Dubois, Doria R.; Marchette, Nyven J.; Trent, Dennis W.; Johnson, Anthony J.

In: Vaccine, Vol. 6, No. 6, 1988, p. 513-518.

Research output: Contribution to journalArticle

Eckels, Kenneth H. ; Yong-Xin, Yu ; Dubois, Doria R. ; Marchette, Nyven J. ; Trent, Dennis W. ; Johnson, Anthony J. / Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. In: Vaccine. 1988 ; Vol. 6, No. 6. pp. 513-518.
@article{796c5ac098de4f7fbd6e8cc3f7f90082,
title = "Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use",
abstract = "The Japanese encephalitis (JE) live-attenuated vaccine virus clone SA14-14-2 was adapted to grow in primary canine kidney (PCK) cell culture, and vaccine seeds and a first lot of vaccine were prepared in these cells. Characterization of the PCK-grown virus by various laboratory and animal tests indicated that passage in PCK did not result in detectable phenotypic or genome changes for this virus clone. Markers of attenuation included small plaque size, lack of intracerebral virulence for weanling mice, minimal neurovirulence for rhesus monkeys and a distinct nucleotide pattern compared to the parent SA14 non-attenuated virus. In addition, the seeds and vaccine were free of any detectable adventitious microbial agents that would render these materials unsafe for human immunization. Small-scale clinical trials of the JE SA14-14-2 PCK vaccine can now proceed to test the human safety of this product.",
author = "Eckels, {Kenneth H.} and Yu Yong-Xin and Dubois, {Doria R.} and Marchette, {Nyven J.} and Trent, {Dennis W.} and Johnson, {Anthony J.}",
year = "1988",
doi = "10.1016/0264-410X(88)90103-X",
language = "English (US)",
volume = "6",
pages = "513--518",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use

AU - Eckels, Kenneth H.

AU - Yong-Xin, Yu

AU - Dubois, Doria R.

AU - Marchette, Nyven J.

AU - Trent, Dennis W.

AU - Johnson, Anthony J.

PY - 1988

Y1 - 1988

N2 - The Japanese encephalitis (JE) live-attenuated vaccine virus clone SA14-14-2 was adapted to grow in primary canine kidney (PCK) cell culture, and vaccine seeds and a first lot of vaccine were prepared in these cells. Characterization of the PCK-grown virus by various laboratory and animal tests indicated that passage in PCK did not result in detectable phenotypic or genome changes for this virus clone. Markers of attenuation included small plaque size, lack of intracerebral virulence for weanling mice, minimal neurovirulence for rhesus monkeys and a distinct nucleotide pattern compared to the parent SA14 non-attenuated virus. In addition, the seeds and vaccine were free of any detectable adventitious microbial agents that would render these materials unsafe for human immunization. Small-scale clinical trials of the JE SA14-14-2 PCK vaccine can now proceed to test the human safety of this product.

AB - The Japanese encephalitis (JE) live-attenuated vaccine virus clone SA14-14-2 was adapted to grow in primary canine kidney (PCK) cell culture, and vaccine seeds and a first lot of vaccine were prepared in these cells. Characterization of the PCK-grown virus by various laboratory and animal tests indicated that passage in PCK did not result in detectable phenotypic or genome changes for this virus clone. Markers of attenuation included small plaque size, lack of intracerebral virulence for weanling mice, minimal neurovirulence for rhesus monkeys and a distinct nucleotide pattern compared to the parent SA14 non-attenuated virus. In addition, the seeds and vaccine were free of any detectable adventitious microbial agents that would render these materials unsafe for human immunization. Small-scale clinical trials of the JE SA14-14-2 PCK vaccine can now proceed to test the human safety of this product.

UR - http://www.scopus.com/inward/record.url?scp=0024264599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024264599&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(88)90103-X

DO - 10.1016/0264-410X(88)90103-X

M3 - Article

VL - 6

SP - 513

EP - 518

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 6

ER -